Key result
Anthracyclines enhance mouse macrophage antibody-dependent cellular cytotoxicity compared to controls.
Why the study?
The modulation of antibody-dependent cellular cytotoxicity by Adriamycin and daunorubicin in treated mice was not fully understood.
Adriamycin and daunorubicin modulate ADCC in mice, initially suppressing it but later enhancing effector cell efficiency, possibly by eliminating suppressor cells.
Peritoneal exudate cells isolated from Adriamycin (AM) or daunorubicin (DM)-treated mice demonstrated an increased ability to mediate antibody-dependent cellular cytotoxicity (ADCC) against antibody-coated chicken red blood cell targets. Following initial suppression of this cell-mediated function 3 days after a single injection, increased effector cell efficiency occurred to an equal degree in both groups of drug treated mice by day 10 compared to controls. This increase in ADCC activity occurred in parallel with a decrease in the total number of peritoneal cells recovered. It is hypothesized that the drugs acted to modulate ADCC in two ways: 1) suppression by induction of suppressor cell activity, and 2) enhancement by elimination of suppressor cells which resulted in increased effector activity of the remaining cells.
No takes yet. Share an insight, caveat, or question.
Pfeifer et al. (1982) studied this question. Adriamycin (AM) or daunorubicin (DM) vs. controls was evaluated on antibody-dependent cellular cytotoxicity (ADCC) against antibody-coated chicken red blood cell targets. Adriamycin or daunorubicin treatment in mice increased the ability of peritoneal exudate cells to mediate antibody-dependent cellular cytotoxicity by day 10 compared to controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: